In the current study, we investigated the HERC1 and HERC2 gene expression in two different cohorts of CML patients during the elapsed time between diagnosis and one year of TKIs (Imatinib and Dasatinib) treatment. This evidence concerns the gene HERC2 and chronic myelogenous leukemia, BCR-ABL1 positive.